

PERSONAL INFORMATION Susana Monge Corella**WORK EXPERIENCE**

-
- June 2010-April 2014 **Researcher**
Instituto de Salud Carlos III (Spain)
Researcher in the national HIV cohort of the AIDS research network (RETICS) and in the EuroCoord project (FP7)
- April 2014-April 2016 **Professor**
Universidad de Alcalá (Spain)
Research and teaching in epidemiology and public health
- May 2016-September 2016 **Field epidemiologist**
Doctors without borders (Chad)
- September 2016-November 2018 **EPIET Fellow**
RIVM (Netherlands)
- January 2019- Present **Epidemiologist**
Ministry of Health (Spain)
Head of Service at the Coordinating Centre for Health Alerts and Emergencies

EDUCATION AND TRAINING

-
- September 1998-July 2004 **Medica Degree**
Autonomous University of Madrid (Spain)
- September 2004-July 2005 **Master in International Cooperation and Development**
Complutense University of Madrid (Spain)
- September 2006-July 2007 **Master in Public Health**
National School of Public Health (Spain)
- May 2006-May 2010 **Medical Specialist in Preventive Medicine and Public Health**
Institute of Health Carlos III (Spain)
- October 2007-June 2010 **Diploma in Research Methods: Statistics and study design in health sciences**
Autonomous University of Barcelona (Spain)
- November 2009-September 2012 **PhD in Health Sciences**
University of Alcalá (Spain)
- December 2019-September 2020 **University Diploma: Dynamic modelling in public health**
UNED - National Distance Education University ()

ADDITIONAL INFORMATION

-
- Expertise** Epidemiological analysis and applied research in infectious diseases

- Publications**
1. Guzman Herrador BR, Rivera Ariza S, Latasa Zamalloa P, Chong Valbuena A, Julian Paches P, Monge S, et al. COVID-19 outbreaks in a transmission control scenario: social and leisure settings and workers in vulnerable conditions identified as main challenges. Spain, early summer 2020. *Euro Surveill.* 2020 Sep;25(35).
 2. Monge S, Garcia-Ortuzar V, Lopez Hernandez B, Lopaz Perez MA, Delacour-Estrella S, Sanchez-Seco MP, Fernandez Martinez B, Garcia San Miguel L, Garcia-Fulgueiras A, Sierra Moros MJ; Dengue Outbreak Investigation Team. Characterization of the first autochthonous dengue outbreak in Spain (August-September 2018). *Acta Trop.* 2020 May;205:105402.
 3. Garcia San Miguel L, Sierra MJ, Vazquez A, Fernandez-Martinez B, Molina R, Sanchez-Seco MP, Lucientes J, Figuerola J, de Ory F, Monge S, Suarez B, Simon F. Phlebovirus-associated diseases transmitted by phlebotominae in Spain: Are we at risk? *Enferm Infecc Microbiol Clin.* 2020 Apr 25:S0213-005X(20)30162-2.
 4. Monge S, Duijster J, Kommer GJ, van de Kasstelee J, Krafft T, Engelen P, Valk JP, de Waard J, de Nooij J, Riezebos-Brilman A, van der Hoek W, van Asten L. Ambulance dispatch calls attributable to influenza A and other common respiratory viruses in the Netherlands (2014-2016). *Influenza Other Respir Viruses.* 2020 Jul;14(4):420-428.
 5. Monge S, Duijster J, Kommer GJ, van de Kasstelee J, Donker GA, Krafft T, Engelen P, Valk JP, de Waard J, de Nooij J, van der Hoek W, van Asten L. Use of Ambulance Dispatch Calls for Surveillance of Severe Acute Respiratory Infections. *Emerg Infect Dis.* 2020 Jan;26(1):148-150.
 6. Monge S, Pijnacker R, van Pelt W, Franz E, Kortbeek LM, Mangen MJ. Accounting for long-term manifestations of *Cryptosporidium* spp infection in burden of disease and cost-of-illness estimations, the Netherlands (2013-2017). *PLoS One.* 2019 Mar 12;14(3):e0213752.
 7. Monge S, Benschop K, Soetens L, Pijnacker R, Hahne S, Wallinga J, Duizer E. Echovirus type 6 transmission clusters and the role of environmental surveillance in early warning, the Netherlands, 2007 to 2016. *Euro Surveill.* 2018 Nov;23(45).
 8. Fakoya I, Alvarez-Del Arco D, Monge S, Copas AJ, Gennotte AF, Volny-Anne A, Wengenroth C, Touloumi G, Prins M, Barros H, Darling KE, Prestileo T, Del Amo J, Burns FM; aMASE Study Team. HIV testing history and access to treatment among migrants living with HIV in Europe. *J Int AIDS Soc.* 2018 Jul;21 Suppl 4:e25123.
 9. Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Perez-Valero I, Montes ML, Valencia E, Martin-Carbonero L, Moreno V, Gonzalez-Garcia J, Rodriguez-Centeno J, Rodes B, Cantos AE, Alejos B, de Miguel R, Arnalich F, Perona R, Arribas JR. Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults. *J Infect Dis.* 2018 Oct 5;218(10):1531-1540.
 10. Monge S, Hahne SJ, de Melker HE, Sanders EA, van der Ende A, Knol MJ. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive *Haemophilus influenzae* type b disease in the Netherlands (2003-16): a case-control study. *Lancet Infect Dis.* 2018 Jul;18(7):749-757.
 11. Monge S, Teunis P, Friesema I, Franz E, Ang W, van Pelt W, Mughini-Gras L. Immune response-eliciting exposure to *Campylobacter* vastly exceeds the incidence of clinically overt campylobacteriosis but is associated with similar risk factors: A nationwide serosurvey in the Netherlands. *J Infect.* 2018 Sep;77(3):171-177.
 12. Monge S, Mollema L, de Melker H, Sanders E, van der Ende A, Knol M. Clinical Characterization of Invasive Disease Caused by *Haemophilus influenzae* Serotype b in a High Vaccination Coverage Setting. *J Pediatric Infect Dis Soc.* 2019 Jul 1;8(3):261-264.
 13. Lodi S, Gunthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, Boender TS, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernan MA; HIV-CAUSAL Collaboration. Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. *AIDS.* 2018 Jan 28;32(3):327-335.
 14. Jarrin I, Monge S, Mocroft A, Sabin A, Touloumi G, Sighem A. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? *HIV Med.* 2018 Jan;19(1):42-48.
 15. Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Perez-Valero I, Montes M, Valencia E, Martin-Carbonero L, Moreno V, Gonzalez-Garcia J, Arnalich F, Mingorance J, Berniches LP, Perona R, Arribas JR. Impact of antiretroviral treatment containing tenofovir difumarate on the telomere length of aviremic HIV-infected patients. *J Acquir Immune Defic Syndr.* 2017 Apr 7. [Epub ahead of print]

16. Monge S, Jarrin I, Pantazis N, Mocroft A, Sabin CA, Touloumi G, van Sighem A, Abgrall S, Dray-Spira R, Spire B, Castagna A, Mussini C, Zangerle R, Hessamfar M, Anderson J, Hamouda O, Ehren K, Obel N, Kirk O, de Monteynard LA, Antinori A, Girardi E, Saracino A, Calmy A, De Wit S, Wittkop L, Bucher HC, Montoliu A, Raben D, Prins M, Meyer L, Chene G, Burns F, Del Amo J. Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Timing of cART initiation in Male and Female Migrants Living with HIV in Western Europe: an observational cohort study (1997-2013). *AIDS*. 2017 Jan 21. [Epub ahead of print]
17. Gonzalez-Baeza A, Arribas JR, Perez-Valero I, Monge S, Bayon C, Martin P, Rubio S, Carvajal F. Vocal emotion processing deficits in HIV-infected individuals. *J Neurovirol*. 2017 Apr;23(2):304-312.
18. del Amo J, Lodi S, Dray-Spira R, Wittkop L, Monge S, Braun D, Vehreschild J, Teira R, Campbell C, d'Arminio Monforte A, Zangerle R, Ghosen J, Kourkounti S, Dabis F, Leport C, Meyer L, Termote M, Kirk O, Porter K, Spire B, Chene G, Egger M. Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe. *AIDS*. 2017 Jan 14;31(2):253-262.
19. Stella-Ascariz N, Montejano R, Pintado-Berninches L, Monge S, Bernardino JI, Perez-Valero I, Montes ML, Mingorance J, Perona R, Arribas JR. Brief Report: Differential Effects of Tenofovir, Abacavir, Emtricitabine, and Darunavir on Telomerase Activity In Vitro. *J Acquir Immune Defic Syndr*. 2017 Jan 1;74(1):91-94.
20. Espelt A, Continente X, Domingo-Salvany A, Dominguez-Berjon MF, Fernandez-Villa T, Monge S, Ruiz-Cantero MT, Perez G, Borrell C; Grupo de Determinantes Sociales de la Salud de la Sociedad Espanola de Epidemiologia. Vigilancia de los Determinantes Sociales en Salud. *Gac Sanit*. 2016 Nov;30 Suppl 1:38-4.
21. V Estrada, S Monge, D Gomez-Garre, P Sobrino, M Masia, J Berenguer, J Portilla, C Vilades, E Martinez and JR Blanco on behalf of the Spanish AIDS Research Network (CoRIS). Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir vs. efavirenz-based antiretroviral therapy. *HIV Medicine*. *HIV Med*. 2016 Oct;17(9):653-61.
22. Gregson J, Tang M, Ndembu N, Hamers RL, Rhee SY, Marconi VC, Diero L, Brooks KA, Theys K, Rinke de Wit T, Arruda M, Garcia F, Monge S, et al. (TenoRes Study Group). Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. *Lancet Infect Dis*. 2016 May;16(5):565-75.
23. Fakoya I, Alvarez-Del Arco D, Monge S, Copas AJ, Gennotte AF, Volny-Anne A, Gopel S, Touloumi G, Prins M, Barros H, Staehelin C, Del Amo J, Burns FM. aMASE (advancing Migrant Access to health Services in Europe): Protocol for a Cross-sectional Study. *JMIR Res Protoc*. 2016 May 16;5(2):e74.
24. Monge S, Jarrin I, Mocroft A, Sabin CA, Touloumi G, van Sighem A, Abgrall S, Dray-Spira R, Spire B, Castagna A, Mussini C, Zangerle R, Hessamfar M, Anderson J, Hamouda O, Ehren K, Obel N, Kirk O, de Monteynard LA, Antinori A, Girardi E, Saracino A, Calmy A, De Wit S, Wittkop L, Bucher HC, Montoliu A, Grarup J, Prins M, Meyer L, Chene G, Burns F, Del Amo J. Mortality in Male and Female Migrants Living with HIV in Western Europe; an observational cohort study (1997 - 2013). *Lancet HIV*. 2015 Dec;2(12):e540-9.
25. Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miro JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Perez-Hoyos S, Jarrin I, Jose S, Sabin C, Hernan MA; HIV-CAUSAL Collaboration. Comparative effectiveness of immediate universal antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. *Lancet HIV*. 2015; 2(8): e335-43.
26. Monge S, Ronda E, Pons-Vigues M, Vives Cases C, Malmusi D, Gil-Gonzalez D. Limitaciones y Recomendaciones Metodologicas en las Publicaciones sobre Salud de la Poblacion Inmigrante en Espana. *Gac Sanit*. 2015 Nov-Dec;29(6):461-3.
27. Alvarez-Del Arco D, Monge S, Rivero-Montesdeoca Y, Burns F, Noori T, Del Amo J. Implementing and expanding HIV testing in immigrant populations in Europe: Comparing guideline's recommendations and expert's opinions. *Enferm Infec Microbiol Clin*. 2017 Jan;35(1):47-51
28. Hernando V, Alvarez-Del Arco D, Alejos B, Monge S, Amato-Gauci AJ, Noori T, Pharris A, Del Amo J. HIV infection in migrant populations in the European Union and European Economic Area in 2007-2012; an epidemic on the move. *J Acquir Immune Defic Syndr*. 2015 Oct 1;70(2):204-11.
29. Fakoya I, Alvarez-del Arco D, Woode-Owusu M, Monge S, Rivero-Montesdeoca Y, Delpech V, Rice B, Noori T, Pharris A, Amato-Gauci AJ, del Amo J, Burns FM. A systematic review of

post-migration acquisition of HIV among migrants from countries with generalised HIV epidemics living in Europe: implications for effectively managing HIV prevention programmes and policy. *BMC Public Health*. 2015 Jun 19;15:561.

30. HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Papanizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernan MA. Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. *Clin Infect Dis*. 2015 Apr 15;60(8):1262-8.
31. Gruber S; Logan RW; Jarrin I; Monge S; Hernan MA. Ensemble learning of Inverse probability weights for marginal structural modeling in large observational datasets. *Stat Med*. 2015 Jan 15;34(1):106-17.
32. Monge S, Diez M, Alvarez M, Guillot V, Iribarren JA, Palacios R, Delgado R, Jaen A, Blanco JR, Domingo P, Portilla J, Perez Elias MJ, Garcia F; Cohorte de la Red de Investigacion en Sida (CoRIS). Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012). *Clin Microbiol Infect*. 2015 Jan;21(1):105.e1-5.
33. Alvarez M, Monge S, Chueca N, Guillot V, Viciano P, Anta L, Rodriguez C, Gomez-Sirvent JL, Navarro G, Santos Ide L, Moreno S, Garcia F; Cohorte de la Red de Investigacion en Sida. Transmitted drug resistance to Rilpivirine in newly diagnosed antiretroviral naive adults. *Clin Microbiol Infect*. 2015 Jan;21(1):104.e1-5.
34. Sobrino-Vegas P, Monge Corella S, Serrano-Villar S, Gutierrez F, Blanco JR, Santos I, del Romero J, Segura F, Portilla J, Guillen SM, del Amo J; CoRIS. Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions. *PLoS One*. 2014 Dec 30;9(12):e116226.
35. Serrano-Villar S, Sobrino-Vegas P, Monge S, Drona F, Hernando A, Montero M, Viciano P, Clotet B, Pineda JA, Del Amo J, Moreno S; CoRIS. Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain. *J Viral Hepat*. 2015 May;22(5):496-503.
36. Boule A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, Sterne JA. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe or North America: a collaborative analysis of prospective studies. *PLoS Med*. 2014 Sep 9;11(9):e1001718.
37. Perez-Valero I, Gonzalez-Baeza A, Miriam Estebanez M, Monge S, Montes-Ramirez ML, Bayon C, Pulido F, Bernardino JI, Zamora FX, Gonzalez-Garcia J, Lagarde M, Hernando A, Arnalich F, Arribas JR. A prospective cohort study of neurocognitive function in HIV-infected aviremic patients treated with 1 or 3 antiretrovirals. *Clin Infect Dis*. 2014 Dec 1;59(11):1627-34.
38. Gonzalez-Baeza A, Carvajal F, Bayon C, Perez-Valero I, Estebanez M, Bernardino JI, Monge S, Lagarde M, Hernando A, Arnalich F, Arribas JR. Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study. *J Neurovirol*. 2014 Aug;20(4):362-70.
39. Monge S, Diez M, Iribarren JA, Campins AA, Montero M, Miro JM, Pulido F, Arazo P, Moreno S, del Amo J, on behalf of CoRIS. Tuberculosis in a cohort of HIV-positive subjects in Spain: presentation, clinical practice and treatment outcomes (2004-2010). *Int J Tuberc Lung Dis*. 2014 Jun;18(6):700-8.
40. S. Monge, Guillot V, Alvarez M, Chueca N, Stella N, Pena A, Delgado R, Cordoba J, Aguilera A, Vidal C, Garcia F, on behalf of CoRIS. Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. *PLoS One*. 2014 Mar 17;9(3):e90710.
41. Hernando V, Alejos B, Monge S, Berenguer J, Anta L, Vinuesa D, Palacios R, Muga R, Moreno S, Jarrin I. All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997--2010. *BMC Infect Dis*. 2013 Aug 20;13(1):382.
42. Alvarez-del Arco D, Monge S, Caro-Murillo AM, Ramirez-Rubio O, Azcoaga A, Belza MJ, Rivero-Montesdeoca Y, Noori T, Del Amo J. HIV testing policies for migrants and ethnic minorities in EU/EEA/EFTA Member States. *Eur J Public Health*. 2014 Feb;24(1):139-44.
43. Perez-Valero I, Gonzalez-Baeza A, Estebanez M, Montes-Ramirez MI, Bayon C, Pulido F, Bernardino JI, Zamora FX, Monge S, Gaya F, Lagarde M, Rubio R, Hernando A, Arnalich F, Arribas JR. Neurocognitive impairment in patients treated with a protease inhibitor monotherapy or triple drug antiretroviral therapy. *PLoS One*. 2013 Jul 25;8(7):e69493.

44. Monge S, Alejos B, Dronda F, Del Romero J, Iribarren J, Pulido F, Rubio R, Miro J, Gutierrez F, Del Amo J; CoRIS. Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain. *HIV Medicine* (2013), 14, 273-283.
45. Monge S, Guillot V, Alvarez M, Pena A, Viciano P, Garcia-Bujalance S, Perez Elias MJ, Iribarren JA, Gutierrez F, Itziar Casado M, Garcia F; CoRIS. Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. *Clin Microbiol Infect*. 2012 Nov;18(11):E485-E490.
46. Alvarez-Del Arco D, Monge S, Azcoaga A, Rio I, Hernando V, Gonzalez C, Alejos B, Caro AM, Perez-Cachafeiro S, Ramirez-Rubio O, Bolumar F, Noori T, Del Amo J. HIV testing and counselling for migrant populations living in high-income countries: a systematic review. *Eur J Public Health*. 2013 Dec;23(6):1039-45.
47. Monge S; Del Romero J; Rodriguez C; de Mendoza C; de Gorgolas M; Cosin J; Dronda F; Perez-Cecilia E; Pena JM; Santos I; Rubio R; del Amo J. Factores sociodemograficos asociados a la progresion de la infeccion por VIH e impacto del TARGA en una cohorte de pacientes seroconvertidores en Madrid (1986-2009). *Enferm Infecc Microbiol Clin*. 2012;30(3):117-123.
48. Monge S, Jarrin I, Perez-Hoyos S, Ferreros I, Garcia-Olalla P, Muga R, Del Romero J, Belda J, Castilla J, Bolumar F, del Amo J, GEMES. Educational level and HIV disease progression before and after the introduction of HAART. A cohort study in 989 HIV seroconverters in Spain. *Sexually Transmitted Infections*. Dec2011. 87(7): 571-6.
49. Valdivia A, Monge-Corella S. Diseases tracked by using Google trends, Spain. *Emerg Infect Dis*. 2010 Jan;16(1):168.
50. Valdivia Perez A, Miguel Benito A, Escortell Mayor E, Monge Corella S. ¿Se puede predecir la epidemia de gripe mediante datos de búsquedas en Internet? *Journal: Gac Sanit*. 2010 Jan-Feb;24(1):95-6.
51. Escortell-Mayor E, Monge-Corella S. Reflexiones sobre la autoría de los estudios científicos. *Rev Clin Esp*. 2009 Nov;209(10):503-10.
52. Valdivia Perez A, Arteaga Perez L, Escortell Mayor E, Monge Corella S, Villares Rodriguez JE. Analisis de las reclamaciones en atención primaria mediante el control estadístico de procesos. *Rev Calid Asist*. 2009 Aug;24(4):155-61.
53. Monge-Corella S, Garcia-Perez J, Aragonés N, Pollán M, Perez-Gomez B, Lopez-Abente G. Lung cancer mortality in towns near paper, pulp and board industries in Spain: a point source pollution study. *BMC Public Health*. 2008 Aug 14;8:288.

Projects

1. Titulo: Accounting for the epidemiological trends of HIV among migrant populations in the EU/EEA.
 Agencia financiadora: ECDC.
 Presupuesto: 60.000
 Duracion: 2014-2015
 Investigadora Principal: Dr. Julia del Amo
2. Titulo: Envejecimiento prematuro de pacientes VIH+: evaluacion in vivo e in vitro del impacto del tratamiento con ITIAN en la longitud de los telomeros.
 Agencia financiadora: Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria).
 Presupuesto: 108.053
 Duracion: 2014-2016
 Investigador Principal: Dr. Jose Ramon Arribas
3. Titulo: Relationship between plasma bilirubin levels and oxidative stress markers in HIV patients on antiretroviral therapy. HYBROS study.
 Agencia financiadora: Fundacion SEIMC-GESIDA
 Presupuesto: 60.000
 Duracion: 2012-2014
 Investigadores Principales: Dr. Jose Ramon Blanco y Dr. Vicente Estrada
4. Titulo: Red de Investigacion en Sida (RIS).
 Agencia financiadora: Instituto de Salud Carlos III- Redes Tematicas de Investigacion Cooperativa (RETICS)

Presupuesto: 2.000.000
Duracion: 2013-2017
Investigador Principal: Dr. Jose Maria Gatell

5. Titulo: Vigilancia de la Transmision de Resistencias a los Antirretrovirales y la Introduccion de Subtipos no-B en CoRIS, la Cohorte de Adultos de la Red de Investigacion en SIDA.
Agencia financiadora: Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria).
Presupuesto: 74.200
Duracion: 2013-2015
Investigador Principal: Dr. Federico Garcia

6. Titulo: Estudio coste-efectividad de la oferta sistemática y voluntaria de la prueba de VIH en Atención Primaria en España (FIS-CEVIH).
Agencia financiadora: Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria).
Presupuesto: 20.000
Duracion: 2013-2016
Investigadora Principal: Dra. Julia del Amo

7. Titulo: Epidemiological update of HIV among migrants in the EU/EEA
Agencia financiadora: ECDC
Presupuesto: 30.000
Duracion: Mayo-Dic 2013
Investigadora Principal: Dr. Julia del Amo

8. Titulo: Deterioro Neurocognitivo y Monoterapia con Inhibidores de la Proteasa. Estudio PICASSO.
Agencia financiadora: Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria).
Presupuesto: 21.000
Duracion: 2011-2013
Investigador Principal: Dr. Jose Ramon Arribas

9. Titulo: Sexual transmission of HIV within migrant groups and implications for effective interventions.
Agencia financiadora: ECDC
Presupuesto: 20.000
Duracion: Abr-Dic 2012
Investigadora Principal: Dr. Fiona Burns

10. Titulo: Determinantes individuales y contextuales del inicio y uso apropiado del tratamiento antirretroviral en una cohorte multicentrica de sujetos VIH-positivos.
Agencia financiadora: Ministerio de Sanidad, Servicios Sociales e Igualdad.
Presupuesto: 19.930
Duracion: 2012-2013
Investigadora Principal: Dr. Julia del Amo

11. Titulo: Analisis de riesgos competitivos en la supervivencia del VIH/SIDA. Aplicabilidad clinica en el estudio de enfermedades que concurren en pacientes VIH+ expuestos a la terapia antirretroviral de gran actividad de la cohorte GEMES.
Agencia financiadora: inisterio de Sanidad, Servicios Sociales e Igualdad.
Presupuesto: 78.000
Duracion: 2012 (1 ano)
Investigador Principal: Dr. Roberto Muga

12. Titulo: EuroCoord - European Network of HIV/AIDS cohort studies to coordinate clinical research on HIV/AIDS at a European and international level.
Agencia financiadora: EU - FP7
Presupuesto: nodo ISCIII 240.000
Duracion: 2011-2016
Investigadora Principal: Dr. Kholoud Porter

13. Titulo: Pais de Probable Adquisicion de la Infeccion por VIH y Barreras de Acceso a la Prevencion y a la Prueba de VIH de la Poblacion Inmigrante en España.
Agencia financiadora: FIPSE (Fundacion para la Investigacion y Prevencion del SIDA en España)

Presupuesto: 83.610

Duracion: 2011-2013

Investigador Principal: Dr. Julia del Amo

14. Titulo: HIV testing and counselling inventory of good practices in migrant populations & ethnic minorities in the EU/EEA/EFTA member states

Agencia financiadora: ECDC

Presupuesto: 60.000

Duracion: 2009-2010

Investigadora Principal: Dr. Julia del Amo

15. Titulo: Red de Investigacion en Sida (RIS).

Agencia financiadora: Instituto de Salud Carlos III - Redes Tematicas de Investigacion Cooperativa (RETICS)

Presupuesto: nodo CNE-ISCI III 682.736

Duracion: 2007-2012

Investigador Principal: Dr. Jose Maria Gatell

16. Titulo: Grupo de Estudio Multicentrico Espanol de Seroconvertidores (GEMES): Estudio del periodo de incubacion del sida y la supervivencia de la infeccion por VIH.

Agencia financiadora: FIPSE (Fundacion para la Investigacion y Prevencion del SIDA en Espana)

Presupuesto: 170.252 (nodo ISCI III 24.000)

Duracion: 2009-2011

Investigador Principal: Dr. Santiago Perez-Hoyos

[Memberships](#) Spanish Epidemiology Society
EPIET Alumni Network

[Other Relevant Information](#)